Proteins in blood could predict prostate cancer a decade in advance, Oxford study finds

Twelve proteins linked to disease more than 15 years before diagnosis; seven tied to aggressive forms

By LineZotpaper

Published21 October 2026

Read Time3 min

Oxford University researchers have identified a set of proteins in the blood that may indicate a man's risk of developing prostate cancer more than a decade before diagnosis, including markers for aggressive, life-threatening disease. The largest study of its kind, published in European Urology, examined blood samples from over 2,500 men and tracked them for an average of 16 years.

Scientists at Oxford Population Health measured more than 6,000 proteins in blood samples from 982 men who later developed prostate cancer and compared them with 1,573 randomly selected participants from the European Prospective Investigation into Cancer and Nutrition. They identified 12 proteins associated with prostate cancer diagnosed more than 15 years later, including GZMK, a protein produced by immune cells that recognise and destroy abnormal cells. This suggests the immune system may keep prostate cancer in check long before it is diagnosed, the team said.

The study also found seven proteins linked to aggressive prostate cancer. One of these, ANKRD1, was present in cancers that spread or caused early death. Other proteins tied to aggressive cancers included those produced by known cancer genes such as ERBB3, KRAS and NRAS. The researchers emphasised this does not mean cancer was already present when blood was collected, but the findings may point to early biological changes.

Dr Zhe Huang, first author and a postdoctoral epidemiologist at Oxford Population Health, said: "Prostate cancer is not one disease. Many prostate cancers grow slowly and may never cause harm, while others are aggressive and can be life-threatening." He noted the work could help "understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future."

Professor Karl Smith-Byrne, a senior author, added: "Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease."

More than 63,000 men are diagnosed with prostate cancer each year in the UK, and more than 12,000 die from it, according to Prostate Cancer UK. The study, part-funded by Cancer Research UK, was also presented at the American Society of Human Genetics annual meeting.

Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said the research "offers important new clues" but more work is needed. Professor Prabhakar Rajan, from Queen Mary University of London, welcomed the study but cautioned that it "does not yet establish that a protein-based blood test can reliably identify men who will develop aggressive prostate cancer or is ready for routine clinical use."

Analysis

Why This Matters

Thousands of men are diagnosed with prostate cancer each year, but current screening methods are limited in distinguishing slow-growing from aggressive cancers.
Identifying men at risk of aggressive disease years earlier could allow for targeted monitoring or preventive strategies, potentially reducing deaths.
The findings open a new avenue for blood-based risk assessment, though further validation and clinical studies are needed before any test becomes available.

Background

Prostate cancer is one of the most common cancers in men, but many cases grow slowly and never cause harm. Aggressive forms, however, are life-threatening. Current diagnosis often relies on PSA testing, which has low specificity and can lead to overdiagnosis. Researchers have long sought biomarkers that can predict aggressive disease early. The Oxford study is the largest to analyse thousands of proteins in blood samples collected years before diagnosis, providing a deep look into early biological changes.

Key Perspectives

[Oxford researchers]: The study identifies specific proteins linked to both early and aggressive prostate cancer, offering potential targets for risk prediction and prevention. They emphasise these are early-stage findings requiring more research. [Critics and cautious experts]: Professor Prabhakar Rajan notes that the study does not yet prove a clinical blood test is reliable. More work is needed to translate protein markers into a validated screening tool. [Cancer Research UK]: The charity sees the findings as important clues, but echoes the need for further investigation before clinical application.

What to Watch

Whether the identified proteins, particularly ANKRD1 and GZMK, are replicated in larger, diverse cohorts.
Development of a commercial or clinical protein-based risk test, which would require prospective trials showing it improves outcomes over current methods.
Ongoing research into biological pathways linking these proteins to cancer initiation and progression, which may lead to new prevention targets.

Sources

Scientists find way to help predict prostate cancer a decade in advance · The Independent UK

Checked

12 claims in this story checked against 1 source: 10 supported.

Show each claim

SupportedBlood proteins could help predict which men may develop prostate cancer more than a decade before diagnosis.The Independent UK: “Scientists have discovered a new way to help predict which men may develop prostate cancer , more than a decade before they do.”
SupportedDr Zhe Huang said, “Prostate cancer is not one disease. Many prostate cancers grow slowly and may never cause harm, while others are aggressive and can be life-threatening.”The Independent UK: ““Prostate cancer is not one disease. Many prostate cancers grow slowly and may never cause harm, while others are aggressive and can be life-threatening.””
SupportedDr Zhe Huang said the work could help “understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future.”The Independent UK: “Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future.”
SupportedProfessor Karl Smith-Byrne said, “Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease.”The Independent UK: ““Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease.””
SupportedDr Iain Foulkes said the research “offers important new clues”.The Independent UK: ““This research offers important new clues…”
SupportedProfessor Prabhakar Rajan said the research “does not yet establish that a protein-based blood test can reliably identify men who will develop aggressive prostate cancer or is ready for routine clinical use.”The Independent UK: ““it does not yet establish that a protein-based blood test can reliably identify men who will develop aggressive prostate cancer or is ready for routine clinical use”.”
SupportedTwelve proteins were linked to prostate cancer diagnosed more than 15 years later.The Independent UK: “Overall, 12 proteins were found that were linked to prostate cancer diagnosed more than 15 years later”
SupportedSeven proteins were linked to aggressive prostate cancer.The Independent UK: “The researchers also identified seven proteins linked to aggressive prostate cancer.”
SupportedThe study examined blood samples from over 2,500 men.The Independent UK: “The research examined blood samples from 982 men who later developed prostate cancer. A further 1,573 men, randomly selected from the European Prospective Investigation into Cancer and Nutrition, were also included.”
Partly supportedParticipants were tracked for an average of 16 years.The Independent UK: “Researchers measured more than 6,000 proteins in the blood and participants were followed up for around 16 years.”
SupportedThis was the largest study of its kind.The Independent UK: “The largest study of its kind found clear biological differences between men who later developed prostate cancer and those who did not.”
Partly supportedProteins produced by ERBB3, KRAS and NRAS were tied to aggressive cancers, without specifying when those cancers were diagnosed.The Independent UK: “These were linked to aggressive prostate cancer diagnosed around a decade later.”